20 December 2016

As leaders of a national consortium of 36 pathology departments and the Pathological Anatomy National Automated Archive (PALGA), Marjolijn Ligtenberg (photo up) and Katrien Grünberg, theme Tumors of the digestive tract received a grant of 1.1 million euro in the ZonMw program personalized medicine oncology to optimize Predictive Analysis for THerapy (PATH) in the Netherlands.

Targeted therapies are a breakthrough in cancer treatment. The big challenge is to predict which patients benefit from these expensive drugs. DNA analysis of tumor tissue is instrumental for this. Fast technological developments and complexity of these analyses demand a coordinated approach for optimal quality and access for cancer patients.

PATH

In the PATH project pathology departments and treating physicians will closely collaborate to meet these aims using the following approaches:
  1. Optimization of predictive diagnostics by innovation and continuous monitoring of diagnostic yield and turnaround times. As proof of concept, a new NGS-based approach developed at Radboudumc laboratory for tumor genetics will be implemented in multiple laboratories. The (cost-) effectiveness of this approach will be compared to other diagnostic procedures.
  2. Establishing a national expert network of multidisciplinary molecular tumor boards that translates complex or unusual DNA aberrations to personalized treatment advice, including possible enrolment in clinical trials. This network will also serve as a platform to interact with patient interest groups and other stakeholders.
  3. The clinical relevance of a large part of the combinations of DNA aberrations and drugs remains to be settled. To enhance this evaluation a synoptic reporting module will be built in PALGA, which enables coupling with treatment and response data as collected by the Netherlands Cancer Registry (at IKNL) and clinical audit registries (DICA). This module will be an indispensable link in the infrastructure for health technology assessment of targeted drugs and evaluation of care. As a first step, the effectiveness of the organization of predictive diagnostics will be evaluated.
ZonMw Goed Gebruik Geneesmiddelen, Personalized Medicine (846001001): Predictive Analysis for Therapy: PATH to Optimising Access to Personalised Cancer Therapy in the Netherlands. 

 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Nieuws home

Related news items


Royal honours for seven Radboud professors

24 April 2020

On Friday 24 April, seven professors from Radboud University and Radboud university medical center received telephone calls from the mayors of their towns informing them that they had been awarded royal honours for their exceptional scientific and social merits.

read more

Study on effect of BCG vaccine on coronavirus infection in the elderly

21 April 2020

Radboud university medical center and UMC Utrecht are working on a joint research project to discover whether the tuberculosis (BCG) vaccine reduces the risk of infection with the coronavirus in people aged 60 or older, or the severity of the symptoms in the event of infection.

read more

Radboudumc researchers publish new insights into COVID-19 Consequences for treatment are now being examined internationally

10 April 2020

Researchers at the Radboud university medical center seem to have found an essential mechanism in the disease process of Covid-19, which has so far been overlooked. If the insight is correct, it probably has important consequences for the treatment of the disease.

read more

Jurgen Fütterer appointed Professor of Image-Guided Oncological Interventions

26 February 2020

RIHS researcher Fütterer is an interventional radiologist and an expert in the field of cancer imaging techniques, image-guided interventions and robotics. He is also Professor at the Robotics and Mechatronics Group at the University of Twente.

read more